The cellular signaling pathways of the prostate play a central role in the induction, maintenance, and progression of prostate cancer (CaP). Neuroendocrine (NE) cells demonstrate attributes that suggest they are an integral part of these signaling cascades. We summarize what is known regarding NE cells in CaP focusing on NE cellular transdifferentiation. This significant event in CaP progression appears to be accelerated by androgen deprivation (AD) treatment. We examine biochemical pathways that may impact NE differentiation in a chronological manner focusing on AD therapy (ADT) as a central event in inducing androgen-independent CaP. Our analysis is limited to the common adenocarcinoma pattern of CaP and excludes small-cell and carcinoid prostatic variants. In conclusion, we speculate on the future of treatment and research in this area.
Introduction
Prostate cancer (CaP) is the most common non-cutaneous malignancy in American men and is predicted to be the third leading cause of cancer deaths for 2006. 1 Although local therapy for CaP is relatively effective, androgen deprivation therapy (ADT) remains the mainstay of treatment for disseminated disease and is principally palliative in nature. Introduced in the 1940s, 2 ADT removes androgen stimulation, initially inducing apoptosis in CaP. However, the disease eventually progresses to an androgen-independent (AI) state with an associated life expectancy of only 15-20 months. Despite continuous research efforts, limited progress has been made in the treatment of advanced CaP in the last 50 years and life expectancy associated with metastatic disease has not changed significantly. 3 ADT, while extending length and quality of life for many patients, also induces biological changes in CaP that may promote progression to an AI state.
The role of prostatic neuroendocrine (NE) cells in this biologic process has recently become the focus of much attention. Known changes in the number, histology, and functions of NE cells during CaP progression indicate that they may play a regulatory role. The fact that the majority of NE cells may not exhibit androgen receptors (ARs) is of special interest in the androgen-deprived patient. 4, 5 In these patients, NE cells may allow continued CaP growth through paracrine stimulation of neoplastic epithelial cells. Indeed, mitogenic and oncogenic activity has been demonstrated for many of the factors NE cells are known to produce.
The purpose of this review is to summarize the latest developments in understanding the role of NE cells in the normal prostate, in CaP, and the effects on potential treatment modalities related to this. Data suggest that ADT may facilitate NE differentiation (NED) and thereby accelerate cellular mechanisms that contribute to the AI state. This review will be structured chronologically around this central event.
NE histology and differentiation
The normal prostate contains a glandular epithelium within intervening fibromuscular stroma. The epithelium can be further subdivided into tall columnar cells that secrete into the lumen of the gland, and cuboidal cells forming a basal layer against the basement membrane. A third type of epithelial cell was first described by Pretl in 1944. 6 These cells are identified by their neurosecretory granules and expression of neuron peptide hormones such as bombesin/gastrin-releasing peptide (GRP), neurotensin (NT), serotonin, calcitonin and parathyroid hormone-related peptide (PTHrP). 7, 8 Based on these findings, they were labeled NE cells, part of the larger amine precursor uptake and decarboxylation (APUD) lineage.
In other organs, the origin of NE cells has been shown to be endodermal stem cells, 9,10 and a similar model was thought to apply to prostatic NE cells. 12 Although disagreement exists regarding the embryonic source of NE cells in the prostate, it is clear that prostatic epithelial cells are remarkably plastic and have the capability to differentiate into NE cells. As described below, the NE cells associated with CaP are phenotypically dissimilar to normal NE cells and function in different ways leading to the conclusion that they probably emerge from transdifferentiation of epithelial cells rather than malignant NE precursors.
Normal function of NE cells
Many secreted types of NE granules are identified by immunohistochemical staining and indicate that different subsets of NE cells exist. This introduces much complexity to the question of their normal function. A general understanding may be obtained by comparisons to NE cells in other organ systems and examination of the individual products secreted by prostatic NE cells.
Prostatic NE cells are part of a larger histological genre known as the APUD system, present in many organs of the body. For example, stomach D cells and G cells produce somatostatin and gastrin, respectively, and many intestinal NE cells secrete various hormones that regulate gut function. In a similar way, it may be inferred that the factors produced by prostatic NE cells regulate prostatic growth, function, and cellular differentiation. Indeed, many of the factors shown to be produced by NE cells are known to support growth and differentiation in the prostate (Table 1) . For example, bombesin/GRP receptors are members of the superfamily of heterotrimeric G-protein-coupled transmembrane-spanning receptors. 13 Binding of these receptors elicits calcium mobilization, thereby promoting growth and cell invasiveness through proteolytic activities in cell lines. [14] [15] [16] [17] If NE cells exert regulatory control over prostatic tissue, the question arises as to what regulates the NE cells. Although some NE cells may express AR, 18 many are AI as they do not contain ARs. 4, 5 However, they do have receptors for epidermal growth factor (EGF) and ErbB2, which suggests they are controlled more by local growth factors from the prostatic stroma than systemic hormones. 19 The expression of the EGF receptor itself is under the control of PTHrP produced by both epithelial cells and NE cells. It has been reported that interleukin (IL)-1b and IL-6 upregulate CgA expression in CaP cell lines, 20 and IL-6 has been shown to induce morphologic change toward an NE phenotype in epithelial cells. 21 To summarize, NE cells express potent neuropeptides that mediate diverse biological processes such as cell growth, differentiation and transformation. In addition, their morphology and distribution within the prostate epithelium suggest a regulatory role similar to APUD cells in other organs of the body. In contrast to other epithelial cells, they are generally AR negative and probably rely on paracrine growth factor control.
Role of NE cells in early CaP
The NE cells in CaP appear morphologically different than those seen in benign tissue and co-express epithelial markers such as prostate-specific antigen (PSA) and NE markers (CgA). 22, 23 It is believed that these cells are the result of transdifferentiation of epithelial cells. 24 Such NED has been experimentally demonstrated in several CaP cell lines using cyclic AMP (cAMP), epinephrine, forskolin, the cytokines IL-1 and IL-6, and as will be seen later, AD conditions. 20, 21, 25, 26 These changes were shown to be reversible when the substances were removed, 27 emphasizing the incredible degree of plasticity exhibited by prostatic epithelial cells. Based on this likely mechanism for generating malignant NE cells, some NE cells may express neuropeptide growth factors before changing morphologically and/or expressing CgA, NSE, etc. In support of this, Iwamura et al. 28 showed increased PTHrP in high-grade prostatic intraepithelial neoplasia before much NED had taken place as measured by common NE markers.
NED is very common in CaP specimens. For example, Bostwick et al. 29 reported a prevalence of 92%. Although wide ranges have been reported (30-100%), this is probably due to different sampling techniques and testing methods. 30 Several varieties of prostatic NED have been described. Two very rare types are small-cell carcinoma and carcinoid tumor, both of which express large numbers of malignant NE cells. The most common type is the typical adenocarcinoma with individual NE cells surrounded by small foci of epithelial CaP cells. This arrangement (Figure 1 ) suggests that the NE cells are producing growth factors supporting surrounding (proliferating) cells. 31, 32 The prognostic significance of NED is controversial. Many studies before 1990 showed a worse prognosis with increasing NED, but subsequent examinations failed to find any correlation independent of tumor Table 1 Selected NE cellular products
Products Action in CaP References
Calcitonin gene family Growth modulation, in vitro resistance to apoptosis, stimulates PTHrP release 45, 66 GRP AI growth factor, mediates migration, in vitro resistance to apoptosis, activates NF-kB 66, 94, 95 Neuropeptide Y Possible angiogenic effect through MAP kinase 96 Parathyroid hormone-related protein Mitogenic, regulates EGF receptor, overexpressed early in CaP 28, 77 Proadrenomedullin N-terminal peptide Angiogenesis and GRP actions through GRP receptor binding 97, 98 Serotonin Mitogen, facilitates AI growth 24, 66, 99 VEGF Angiogenesis, promotes growth and motility in AI manner 48, 100 Abbreviations: AI, androgen-independent; CaP, prostate cancer; GRP, gastrin-releasing peptide; MAP, mitogen-activated protein; NF-kB, nuclear factor-kappa B; PTHrP, parathyroid homone-related peptide; VEGF, vascular endothelial growth factor.
Neuroendocrine differentiation in prostate cancer EC Nelson et al grade or androgen responsiveness. 7 The controversy continues with some recent studies showing an independent negative correlation between serum CgA and survival in AI CaP, 33, 34 but others showing no prognostic correlation, 35 or improved outcomes with higher CgA. 36 These authors all agree that the serum CgA continues to be a valid marker of progression, but the complex biology of NED makes direct correlation with prognosis difficult. Cussenot et al. 37 studied CgA and NSE serum levels in CaP patients before ADT. Although most elevations of serum markers were found in AI tumors, some were not, leading them to theorize a role for NED in the progression of CaP before AD. Their study corroborated findings by Hoosein et al. 38 that NED markers correlated more with metastasis than locally advanced disease.
The role of NE cells in the development and progression of CaP is suggested by their central role in cell signaling pathways and several of these will be briefly outlined including bombesin/GRP, serotonin, PTHrP and possible pathways involved in angiogenesis (Figure 2) . A negative regulator of proliferation, somatostatin, will also be discussed.
Bombesin/GRP is a potent mitogenic neuropeptide shown to stimulate CaP growth in cell culture, 39 probably through its ability to induce c-fos and c-myc, thereby deregulating the cell cycle. 40 GRP receptors are known to be distributed throughout the human prostate and Markwalder and Reubi 41 showed they are overexpressed in CaP. Bombesin/GRP also causes CaP cell lines PC-3 and LNCaP to acquire greater invasive potential. 42 Serotonin is produced by most NE cells and is known to be associated with malignant transformation. 7, 43 Dizeyi et al. 44 showed several types of serotonin receptors exist in CaP tissue and cell lines. Higher grade cancer was shown to express a greater number of receptors and tissue growth was regulated by serotonin agonists and antagonists. The pathways by which serotonin acts are complex due to multiple receptor binding capabilities. It has been suggested that serotonin may be related to the potent oncoprotein ras 10 downstream from EGF receptors.
PTHrP is predominantly expressed in fetal tissues but is also produced by NE cells. It is overproduced by CaP tissue lines and can stimulate growth in a paracrine manner. 45 PSA cleaves PTHrP destroying its ability to Neuroendocrine
This has led to the suggestion that as PSA expression decreases with ADT and CaP progression, PTHrP's growth-promoting activity increases. 19 Angiogenesis is a necessary component of neoplastic growth because of increased energy requirements. NED is correlated with overall microvessel density in CaP. In addition, increased microvessel density is seen surrounding areas of NED and this effect is independent of tumor grade. 46 Several products of NE cells are possible mediators of this effect. Vascular endothelial growth factor (VEGF) is produced by some NE cells, 47 and VEGF staining NE cell density correlates with microvessel density. 48 Although bombesin/GRP probably does not directly stimulate angiogenesis through tyrosine kinases, 49 it may stimulate the nuclear factor-kappa B (NF-kB) angiogenesis pathway or enhance the angiogenic effects of growth factors by transactivating the EGF receptor. [50] [51] [52] The fact that the EGF receptor is overexpressed in CaP may enhance this effect. 53 Somatostatin is the one neuropeptide that may have a restraining influence upon prostatic growth and possibly neoplastic transformation. NE cells not only produce somatostatin, they also have receptors indicating autocrine as well as paracrine function. 54 In CaP cells, somatostatin induces cell-cycle arrest and apoptosis, 55 perhaps through receptor type 3, which induces Bax. 56 Somatostatin may inhibit neovascularization and prostatic growth both directly and through indirect effects mediated by insulin-like growth factor (IGF)-1. Somatostatin decreases growth hormone (GH) release by the liver, which in turn decreases IGF-1 release. 56 Acromegalic patients have increased GH and IGF-1, and the somatostatin agonist octreotide has been shown to decrease prostate size in a cohort of these patients. 57 To summarize, NE cells express potent neuropeptides that mediate diverse biological processes such as cell growth, differentiation, transformation and invasion. Although NE cells do not stain for proliferative antibodies, they may be a source of paracrine factors that support CaP growth and progression. All of these complex interactions between signal-transduction pathways are undoubtedly involved in prostatic homeostasis. This fine balance may be disturbed not only by preexisting genetic faults but also via environmental toxins and carcinogens, diet, and the stress response, all of these acting through the microcellular hormonal milieu. Many of these microcellular environmental pathways converge through G-protein-coupled receptors via cAMP, protein kinase A and tyrosine kinases to activate mitogenactivated protein (MAP) kinases. Increasing aberrant activation of these pathways is independent of androgens, utilizing instead a complex interplay between classical growth factors and neuropeptides.
NE cells during ADT
The current treatment of metastatic CaP consists of medical or surgical AD. The prostatic microenvironmental conditions brought on by ADT apparently play a central role in the progression of CaP to the AI state. NE cells are thought to play an important part in effecting this change based on several lines of evidence from both in vitro and in vivo studies.
Jongsma et al. 58 demonstrated that PC310 cells differentiate along NE lines when they are androgen deprived. Figure 3) , with the addition of IL-6, 21 IL-8 59 and neuropeptides. 60 Human prostatic epithelial cells are similarly plastic and undergo NED in an AD mouse xenograft. 61 CaP patients treated with ADT demonstrate higher levels of CgA compared to androgen normal controls. 62 When patients undergo surgical resection, prostatic specimens showed significantly increased NED in patients treated with neoadjuvant ADT compared to surgery only. 63 Examination of gene expression shows higher levels of CgA mRNA in androgen-deprived CaP vs benign tissue. 62 Feldman and Feldman 64 have described a system for classifying mechanisms of AI growth during ADT into five categories. These are by no means mutually exclusive and may all be operative. Two of their categories form a useful framework for discussing the various possible actions of NE cells in the larger tissue microenvironment, specifically their possible role in supporting AI growth of CaP epithelial cells.
AD of LNCaP cells results in NED (
The 'outlaw receptor pathway' causes androgenic effects via crosstalk between the AR and other signaling pathways. The final common pathway for these effects seems to be phosphorylation of residues on the AR causing activation of downstream effects, probably through stimulation of MAP kinase. 59, 65 Theoretically, these signaling pathways can be activated by various biogenic amines produced by NE cells. 7 Jongsma et al.
66
showed that some androgen-depleted CaP cell lines can proliferate when stimulated by GRP, a neuropeptide produced by NE cells. The gradual shift of normal to uncontrolled stimulation of proliferation may be accelerated by ADT through stimulation of greater growth factor production as shown by Culig et al. 67 for EGF. Alternatively, decreased The 'bypass pathway' includes mechanisms that no not require androgens or the AR. The inhibition of apoptosis is an important mechanism for the progression of neoplasia and several mechanisms in CaP have been studied. Bcl-2 is a gene product that blocks apoptosis and is not normally expressed by prostate epithelium. 70 The expression of this gene directly correlates with androgen responsiveness and has been shown to be induced upon ADT in a mouse xenograft model. 71, 72 Epithelial cells surrounding NE cells have higher levels of Bcl-2, suggesting that the microcellular environment produced by them induces greater cell survival. 73 In addition, the NE cells express survivin, another antiapoptotic substance. 74 Growth factors may not only promote growth through outlaw receptor pathways, they may also inhibit apoptosis. Neuropeptides endothelin-1, bombesin, and growth factor IGF-1 activate the IGF-1 receptor, which phosphorylates AKT, a serine/threonine kinase. Activated AKT induces a strong antiapoptotic cellular signal. 75 The activity of AKT is opposed by PTEN (phosphatase and tensin homolog) and loss of PTEN is correlated with high-grade CaP. 76 If IGF-1 activity is increased because of the AD-mediated decrease in IGFBP, the AKT pathway would overcome the inhibition of PTEN even if it has not been lost to mutation. Activation of the AKT pathway is probably important in AI progression. 77 To summarize the role of NE cells in the AI state, it has been demonstrated that the products of NE cells stimulate AI growth and increasing anaplasia. All CaP cells from cell lines and patient samples have receptors for bombesin or NT. 41 PC-3 cells display a growth response to NT 16 and invasive/motility responses to bombesin. 17, 42, 78 Elevated expression of GRP receptors are found in CaP specimens. 41, 79 Likewise, androgensensitive LNCaP cells were shown to become invasive after bombesin treatment. 42 These and other findings suggest that NED of CaP cells may be a central link in supporting AI CaP growth under AD conditions.
NE cells after ADT
Following ADT, NE features are an independent prognostic factor for progression of CaP. 80 Following neoadjuvant ADT, surgical specimens showed greater NED compared to non-treated controls. 63 In a retrospective study of CaP patients treated with chemotherapy, Cabrespine et al. 35 showed that CgA serum levels following ADT were independently related to treatment duration and were helpful in assessing patient response to chemotherapy.
It is unlikely that ADT always initiates NED or that this is an important feature in all CaP patients. However, if it is true that ADT of CaP tends to promote NED and supports continued progression of the tumor towards AI, then the natural question arises, can CaP associated with NED be treated?
Treatment
Treatment of AI CaP is the focus of intense research. Only those strategies that directly impact NE cellular signaling will be discussed here. These treatments can be separated into adjunctive and salvage categories. The former combines with ADT to prevent NED from taking place, while the latter attempts to block the biochemical pathways that result from existing NED tumors.
Adjunctive treatment strategies are very limited. We are not aware of any currently used adjunctive medications intended to prevent NED. So far, the only treatments intended to do this involve variations in the method or temporal aspects of AD. Sciarra and Di Silverio 81 have randomized patients with biochemical progression following prostatectomy into two monotherapy groups: medical castration or antiandrogen. They showed a significantly lower CgA level in the group treated with antiandrogen, although both groups showed significant increases.
Intermittent androgen deprivation (IAD) was developed as an attempt to delay the biochemical events that lead to AI during continuous ADT. The known side effects of ADT and concern for quality of life in advanced CaP have also fueled interest. At least one study has shown that IAD may also prevent or delay NED in locally advanced disease when compared to CAD. 82 Metastatic disease also showed a trend toward lower serum CgA levels.
There are many treatments attempting to inhibit NED or at least block pathways NE cells use to drive CaP progression. Three known pathways that have excited interest are bombesin/GRP, serotonin and somatostatin. Antibodies against bombesin/GRP were shown to inhibit prostate cell line growth through MAP kinase pathways. 83 Several studies have shown in vitro inhibition of CaP growth using serotonin inhibitors. 44, 84, 85 Somatostatin has been used for various endocrine tumors for some time with varied success. 7 The actions of somatostatin in CaP are more complex and the treatment effect may be through secondary mediators such as decreasing certain growth factors from NE cells. 86 In addition, multiple somatostatin receptor types exist and different medications show different affinities. A recent review of the literature including seven studies using somatostatin analogues as monotherapy showed 'negative results'. 87 Direct growth factor antagonists of many varieties have been tested with mixed results. For example, suramin binds several growth factors and has shown moderate activity in CaP. 88 Targeting downstream effectors of the pathways listed above may allow inhibition of multiple growth factors with one treatment. Src, a non-receptor tyrosine kinase activated by G-protein-coupled receptors, activates signal transducers and activator of transcription 3, which in turn activates transcription of VEGF, cyclinD1 and c-myc. Research at our institution has demonstrated the importance of Src as a central signal-transduction molecule in NED. 60 An NCI-sponsored phase II trial of the Src inhibitor AZD0530 as treatment for AI CaP is planned to start by early 2007.
Another indirect method of targeting growth factors is growth hormone-releasing hormone (GHRH) antagonists. These medications have recently undergone Neuroendocrine differentiation in prostate cancer EC Nelson et al improvements in efficacy and duration of action and have shown activity in vitro and in xenografts. 89 Several combination therapy protocols have been used. GHRH antagonists in conjunction with bombesin/ GRP antagonists showed additive interference with IGF and EGF pathways in PC-3 cell lines and xenografts. 89 The authors suggest this may allow future adjuvant use of these types of medication. Sciarra et al. 90 suggest that somatostatin may influence the microenvironment in which CaP cells reside, allowing other treatments to more effectively destroy the malignancy. Recognizing the direct cytotoxic effects of estrogen on CaP, 91 they used the somatostatin agonist lanreotide in combination with ethinyl estradiol, theorizing a synergistic effect. Fourteen of 20 stage D3 patients demonstrated extended response time and symptomatic improvement. In addition, serum CgA decreased significantly, suggesting that a decrease in NE cell number or activity may be partially responsible for their results.
Chemotherapy targets dividing cells to induce genomic damage and apoptosis. Although NE cells are typically thought to be post-mitotic, 5 at least one paper claims otherwise. 92 Modern chemotherapy regimens may be useful according to a recent report, 35 which demonstrated significant decreases in CgA in treated AI CaP patients.
One tremendous difficulty in developing new treatment strategies is assessing effectiveness in reaching the intended target. The focal nature of NED makes direct tissue analysis less accurate than serum markers such as CgA. 93 However, all currently used serum markers are expressed by non-NE cells and therefore are affected by overall prostatic tissue volume rather that only NE cell number. Measuring patient outcomes, although helpful in identifying useful treatments, gives no information on specific pathways. Development of new markers for NED is a needed area of research. Other potential methods include radiolabeled monoclonal antibody imaging studies such as somatostatin receptor scintigraphy. Non-invasive visualization of various receptors in NE tissue shows great promise in treatment assessment.
Conclusions
In summary, AR-negative NE cells are present in normal prostatic tissue and may play a role in supporting initial neoplastic changes. ADT may induce microenvironmental changes that increase the activity of these cells. It is at least certain that they are selected for due to the lack of androgen. NE cells are capable of inducing transdifferentiation toward an NE phenotype in surrounding epithelial cells. The substances excreted by the increasing number of NE cells support the proliferation of existing CaP in an AI manner progressively increasing independence from androgen control. Greater understanding of these early post-castration molecular events will allow targeted adjunctive treatment of NED, thus decreasing the number of CaP cells that escape from hormonal control. New markers and associated imaging techniques for NED will allow molecular expression profiling, thus individualizing treatment based on the patient's unique microcellular environment.
